天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Home Cart 0 Sign in  

[ CAS No. 100-81-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 100-81-2
Chemical Structure| 100-81-2
Structure of 100-81-2 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 100-81-2 ]

Related Doc. of [ 100-81-2 ]

Alternatived Products of [ 100-81-2 ]
Product Citations

Product Citations

Dube, Phelelisiwe S. ; Legoabe, Lesetja J. ; Jordaan, Audrey , et al. DOI: PubMed ID:

Abstract: Mycobacterium tuberculosis (Mtb) has an impermeable cell wall which gives it an inherent ability to resist many antibiotics. DprE1, an essential enzyme in Mtb cell wall synthesis, has been validated as a target for several TB drug candidates. The most potent and developmentally advanced DprE1 inhibitor, PBTZ169, is still undergoing clin. development. With high attrition rate, there is need to populate the development pipeline. Using a scaffold hopping strategy, we imprinted the benzenoid ring of PBTZ169 onto a quinolone nucleus. Twenty-two compounds were synthesized and screened for activity against Mtb, with six compounds exhibiting sub micromolar activity of MIC90 <0.244 μM. Compound 25 further demonstrated sub-micromolar activity when evaluated against wild-type and fluoroquinolone-resistant Mtb strains. This compound maintained its sub-micromolar activity against a DprE1 P116S mutant strain but showed a significant reduction in activity when tested against the DprE1 C387S mutant.

Keywords: DprE1 ; Quinolone ; Nitro compounds ; Mycobacterium tuberculosis ; Benzothiazinone

Purchased from AmBeed: ; ; ; ; ; ; ; ;

Product Details of [ 100-81-2 ]

CAS No. :100-81-2 MDL No. :MFCD00008118
Formula : C8H11N Boiling Point : No data available
Linear Structure Formula :- InChI Key :RGXUCUWVGKLACF-UHFFFAOYSA-N
M.W : 121.18 Pubchem ID :66015
Synonyms :

Calculated chemistry of [ 100-81-2 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 9
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.25
Num. rotatable bonds : 1
Num. H-bond acceptors : 1.0
Num. H-bond donors : 1.0
Molar Refractivity : 39.08
TPSA : 26.02 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.09 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.68
Log Po/w (XLOGP3) : 1.34
Log Po/w (WLOGP) : 1.3
Log Po/w (MLOGP) : 1.87
Log Po/w (SILICOS-IT) : 1.92
Consensus Log Po/w : 1.62

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 2.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.86
Solubility : 1.66 mg/ml ; 0.0137 mol/l
Class : Very soluble
Log S (Ali) : -1.49
Solubility : 3.94 mg/ml ; 0.0325 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -2.78
Solubility : 0.2 mg/ml ; 0.00165 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.0

Safety of [ 100-81-2 ]

Signal Word:Danger Class:8
Precautionary Statements:P501-P210-P264-P280-P370+P378-P303+P361+P353-P301+P330+P331-P363-P304+P340+P310-P305+P351+P338+P310-P403+P235-P405 UN#:2735
Hazard Statements:H314-H227 Packing Group:Ⅲ
GHS Pictogram:

Application In Synthesis of [ 100-81-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 100-81-2 ]

[ 100-81-2 ] Synthesis Path-Downstream   1~6

  • 1
  • [ 89-93-0 ]
  • [ 2620-50-0 ]
  • [ 6068-70-8 ]
  • [ 5824-40-8 ]
  • [ 33166-49-3 ]
  • [ 51586-20-0 ]
  • [ 100-81-2 ]
  • [ 108-44-1 ]
  • [ 618-36-0 ]
  • [ 95-68-1 ]
  • [ 87-62-7 ]
  • [ 88-05-1 ]
  • [ 95-53-4 ]
  • [ 91-00-9 ]
  • 2,2,2-triphenyl-<i>N</i>-<i>m</i>-tolyl-acetamide [ No CAS ]
  • 2,2,2-triphenyl-<i>N</i>-(1-phenyl-ethyl)-acetamide [ No CAS ]
  • 2,2,2-triphenyl-<i>N</i>-<i>o</i>-tolyl-acetamide [ No CAS ]
  • <i>N</i>-(3-methyl-benzyl)-2,2,2-triphenyl-acetamide [ No CAS ]
  • 3,3,3-triphenyl-<i>N</i>-<i>o</i>-tolyl-propionamide [ No CAS ]
  • 3,3,3-triphenyl-<i>N</i>-<i>m</i>-tolyl-propionamide [ No CAS ]
  • <i>N</i>-(2-methyl-benzyl)-2,2,2-triphenyl-acetamide [ No CAS ]
  • 3,3,3-triphenyl-<i>N</i>-(1-phenyl-ethyl)-propionamide [ No CAS ]
  • <i>N</i>-(2,6-dimethyl-phenyl)-2,2,2-triphenyl-acetamide [ No CAS ]
  • <i>N</i>-(2,4-dimethyl-phenyl)-2,2,2-triphenyl-acetamide [ No CAS ]
  • <i>N</i>-(2,3-dimethyl-benzyl)-2,2,2-triphenyl-acetamide [ No CAS ]
  • <i>N</i>-(3-methyl-benzyl)-3,3,3-triphenyl-propionamide [ No CAS ]
  • <i>N</i>-(2,4-dimethyl-phenyl)-3,3,3-triphenyl-propionamide [ No CAS ]
  • <i>N</i>-(2-methyl-benzyl)-3,3,3-triphenyl-propionamide [ No CAS ]
  • <i>N</i>-benzhydryl-2,2,2-triphenyl-acetamide [ No CAS ]
  • <i>N</i>-(2,6-dimethyl-phenyl)-3,3,3-triphenyl-propionamide [ No CAS ]
  • 2,2,2-triphenyl-<i>N</i>-(2,4,6-trimethyl-phenyl)-acetamide [ No CAS ]
  • <i>N</i>-(2,3-dimethyl-benzyl)-3,3,3-triphenyl-propionamide [ No CAS ]
  • <i>N</i>-benzo[1,3]dioxol-5-ylmethyl-2,2,2-triphenyl-acetamide [ No CAS ]
  • 3,3,3-triphenyl-<i>N</i>-(2,4,6-trimethyl-phenyl)-propionamide [ No CAS ]
  • <i>N</i>-benzhydryl-3,3,3-triphenyl-propionamide [ No CAS ]
  • <i>N</i>-benzo[1,3]dioxol-5-ylmethyl-3,3,3-triphenyl-propionamide [ No CAS ]
  • C39H31NO [ No CAS ]
  • N-triphenylmethyl-3,3',3''-triphenylpropanamide [ No CAS ]
  • 2
  • [ 137640-84-7 ]
  • [ 100-81-2 ]
  • C21H17F3N2O2 [ No CAS ]
  • 3
  • [ 23020-15-7 ]
  • [ 100-81-2 ]
  • [ 1531592-19-4 ]
  • 4
  • [ 4654-08-4 ]
  • [ 100-81-2 ]
  • [ 1607800-55-4 ]
YieldReaction ConditionsOperation in experiment
100% With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In N,N-dimethyl-formamide; at 0 - 20℃; for 8h;Inert atmosphere; General procedure: To a solution of o-10 (915 mg, 4.71 mmol) in DMF (15.7 mL), 3-methylbenzylamine (701 muL, 5.65 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC: 1.20 g, 6.26 mmol) and N,N-dimethyl-4-aminopyridine (DMAP: 153 mg, 1.25 mmol) were added at 0 C. The mixture was stirred for 7.5 h at room temperature, then water and ethyl acetate were added at 0 C. The organic layer was separated and washed with water and brine. The combined aqueous layers were extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate and concentrated in vacuo. Further purification was carried out by silica gel column chromatography (eluent: hexane/ethylacetate = 1:1) to give o-13 (1.38 g, 99 %) as a pale yellow oil. IR (neat) 3296, 2943, 1643, 1608, 1593, 1535, 1456, 1240 cm-1; 1HNMR (400 MHz, CDCl3) d 1.65-1.78 (m, 4H), 2.30 (t, J = 6.8 Hz,2H), 2.33 (s, 3H), 2.65 (br t, J = 7.2 Hz, 2H), 4.40 (d, J = 5.2 Hz, 2H),5.74 (br, 1H), 5.98 (s, 1H), 6.78 (dd, J = 0.8 Hz, 7.6 Hz, 1H), 6.82(td, J = 7.6 Hz, 0.8 Hz, 1H), 7.05-7.10 (m, 5H), 7.22 (br t,J = 7.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) d 21.3, 25.4, 29.3, 29.5, 36.2, 43.6, 115.6, 120.0, 124.8, 127.0, 128.2, 128.4, 128.6 (2C), 130.0, 137.9, 138.4, 154.3, 173.7; HRMS-ESI (m/z): [M+Na+] calcd for C19H23NO2Na, 297.1729; found, 297.1728. m-13 (65.3 mg, 85 %): IR (neat) 3282, 2931, 1645, 1587, 1533, 1455, 1275, 1240,1157 cm-1; 1H NMR (400 MHz, CDCl3) d 1.58-1.76 (m, 4H), 2.22 (t, J = 6.8 Hz, 2H), 2.33 (s, 3H), 2.58 (t, J = 7.2 Hz, 2H), 4.39 (d,J = 5.6 Hz, 2H), 5.61 (br, 1H), 5.69 (br, 1H), 6.64-6.68 (m, 2H), 6.71 (br d, J = 7.6 Hz, 1H), 7.04-7.14 (m, 4H), 7.22 (t, J = 7.6 Hz,1H); 13C NMR (100 MHz, CDCl3) d 21.3, 25.2, 30.6, 35.3, 36.5,43.7, 112.9, 115.4, 120.2, 124.8, 128.3, 128.6 (2C), 129.4, 137.8, 138.4, 143.7, 156.3, 173.4; HRMS-ESI (m/z): [M+Na+] calcd for C19H23NO2Na, 297.1729; found, 297.1729. p-13 (905 mg, quant.): IR(neat) 3290, 2925, 1641, 1612, 1541, 1514, 1446, 1230 cm-1; 1HNMR (400 MHz, CDCl3) d 1.57-1.73 (m, 4H), 2.30 (t, J = 7.2 Hz,2H), 2.33 (s, 3H), 2.54 (t, J = 7.6 Hz, 2H), 4.39 (d, J = 5.6 Hz, 2H), 5.69 (br, 1H), 5.74 (br, 1H), 6.74 (d, J = 8.4 Hz, 2H), 6.99 (d,J = 8.4 Hz, 2H), 7.04-7.10 (m, 3H), 7.22 (t, J = 7.2 Hz, 1H); 13CNMR (100 MHz, CDCl3) d 21.2, 25.2, 31.1, 34.6, 36.4, 43.5, 115.2(2C), 124.7, 128.1, 128.4, 128.5, 129.1 (2C), 133.2, 137.7, 138.2,154.5, 173.7; HRMS-ESI (m/z): [M+ Na+] calcd for C19H23NO2Na, 297.1729; found, 297.1728.
  • 5
  • [ 6624-49-3 ]
  • [ 100-81-2 ]
  • isoquinoline-3-carboxylic acid 3-methylbenzylamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
General procedure: The compounds 1-9 were synthesized using themixed anhydrides method of peptide synthesis (18).The suitable acid (10 mM) was dissolved in DMF(15 mL) and THF (15 mL) was added. Next N-methylmorpholine (10 mM, 1.1 mL) was added andthe mixture was stirred under nitrogen and chilled to-15 O C. Isobutyl chloroformate (10 mM, 1.3 mL) wasadded dropwise to keep the temperature below -15 O C. Then, the suitable amine: 2- or 4-fluorobenzy-lamine (2-F-BZA, 4-F-BZA); 2- or 4-methoxyben-zylamine (2-OMe-BZA, 4-OMe-BZA); 3- or 4-methylbenzylamine (3-Me-BZA, 4-Me-BZA) or 1-naphthylmethylamine (10 mM) in THF was added insmall portions and the reaction mixture was stirred at -15 O C for 30 min and at room temperature for 1 h.The solution was concentrated in vacuo and theresidue was dissolved in CHCl 3 (40 mL). This solu-tion was washed with 20 mL portions of 1M HCl,saturated NaHCO 3 solution and saturated NaCl solu-tion, then dried with anhydrous MgSO 4 , filtered andconcentrated in vacuo. The obtained compoundswere purified by crystallization with EtOAc/hexaneor MeOH/Et 2 O. All stages of the synthesis were con-trolled by TLC. The purity and identity of the finalcompounds were determined by HPLC, elementalanalyses, 1 H NMR, MS. The elemental analyses werewithin ± 0.4percent of the theoretical value. The analyticaldata confirmed that the purity of the products was ?95percent. The general procedure for the synthesis of theobtained compounds is shown in Schemes 1 and 2.
  • 6
  • [ 30982-08-2 ]
  • [ 100-81-2 ]
  • C18H21NO4 [ No CAS ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 100-81-2 ]

Aryls

Chemical Structure| 2018-90-8

[ 2018-90-8 ]

1-(2-Naphthyl)methanamine

Similarity: 0.96

Chemical Structure| 74788-82-2

[ 74788-82-2 ]

2,6-Dimethylbenzylamine

Similarity: 0.92

Chemical Structure| 40393-99-5

[ 40393-99-5 ]

Mesitylmethanamine

Similarity: 0.92

Chemical Structure| 89-93-0

[ 89-93-0 ]

o-Tolylmethanamine

Similarity: 0.92

Chemical Structure| 39180-84-2

[ 39180-84-2 ]

N-Methyl-1-(m-tolyl)methanamine

Similarity: 0.88

Amines

Chemical Structure| 2018-90-8

[ 2018-90-8 ]

1-(2-Naphthyl)methanamine

Similarity: 0.96

Chemical Structure| 74788-82-2

[ 74788-82-2 ]

2,6-Dimethylbenzylamine

Similarity: 0.92

Chemical Structure| 40393-99-5

[ 40393-99-5 ]

Mesitylmethanamine

Similarity: 0.92

Chemical Structure| 89-93-0

[ 89-93-0 ]

o-Tolylmethanamine

Similarity: 0.92

Chemical Structure| 39180-84-2

[ 39180-84-2 ]

N-Methyl-1-(m-tolyl)methanamine

Similarity: 0.88

; ;